CRNX Stock Overview
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
+ 1 more risk
Crinetics Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$18.59|
|52 Week High||US$28.95|
|52 Week Low||US$15.91|
|1 Month Change||10.72%|
|3 Month Change||-5.49%|
|1 Year Change||-5.54%|
|3 Year Change||-25.67%|
|5 Year Change||n/a|
|Change since IPO||-24.15%|
Recent News & Updates
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2; Results from both studies expected 2023. Paltusotine is also being explored for the treatment of patients with neuroendocrine tumors in a phase 2 study. Phase 1 proof of concept was established with CRN04777 for treatment of patients with congenital hyperinsulinism; phase 2 study expected to start 2nd half of 2022. Crinetics has around $444.7 million in cash including the most recent offering done in April of 2022, it believes that all this cash should be enough to fund its operations into the 2nd half of 2024.
|CRNX||US Biotechs||US Market|
Return vs Industry: CRNX exceeded the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: CRNX exceeded the US Market which returned -18.4% over the past year.
|CRNX Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CRNX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CRNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.
Crinetics Pharmaceuticals Fundamentals Summary
|CRNX fundamental statistics|
Is CRNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRNX income statement (TTM)|
|Cost of Revenue||US$94.92m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.23|
|Net Profit Margin||-2,835.99%|
How did CRNX perform over the long term?See historical performance and comparison
Is CRNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRNX?
Other financial metrics that can be useful for relative valuation.
|What is CRNX's n/a Ratio?|
Price to Book Ratio vs Peers
How does CRNX's PB Ratio compare to its peers?
|CRNX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ARQT Arcutis Biotherapeutics
KYMR Kymera Therapeutics
KDNY Chinook Therapeutics
CRNX Crinetics Pharmaceuticals
Price-To-Book vs Peers: CRNX is good value based on its Price-To-Book Ratio (3.3x) compared to the peer average (4.1x).
Price to Earnings Ratio vs Industry
How does CRNX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CRNX is expensive based on its Price-To-Book Ratio (3.3x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is CRNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CRNX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CRNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRNX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Crinetics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRNX's revenue (71.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CRNX's revenue (71.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRNX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Crinetics Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRNX is currently unprofitable.
Growing Profit Margin: CRNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRNX is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.
Accelerating Growth: Unable to compare CRNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CRNX has a negative Return on Equity (-39.39%), as it is currently unprofitable.
Discover strong past performing companies
How is Crinetics Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRNX's short term assets ($328.2M) exceed its short term liabilities ($20.3M).
Long Term Liabilities: CRNX's short term assets ($328.2M) exceed its long term liabilities ($10.0M).
Debt to Equity History and Analysis
Debt Level: CRNX is debt free.
Reducing Debt: CRNX has no debt compared to 5 years ago when its debt to equity ratio was 1.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRNX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CRNX has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 41.2% each year.
Discover healthy companies
What is Crinetics Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRNX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
R. Struthers (59 yo)
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
CEO Compensation Analysis
Compensation vs Market: R.'s total compensation ($USD4.14M) is about average for companies of similar size in the US market ($USD4.02M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
Experienced Management: CRNX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: CRNX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.3%.
Crinetics Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Crinetics Pharmaceuticals, Inc.
- Ticker: CRNX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$994.673m
- Shares outstanding: 53.51m
- Website: https://www.crinetics.com
Number of Employees
- Crinetics Pharmaceuticals, Inc.
- Building No. 2
- 10222 Barnes Canyon Road
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.